- Conditions
- Attention Deficit Hyperactivity Disorder, Substance Use Disorder
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 15 Years to 30 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 128
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson's Disease, Idiopathic
- Interventions
- Methylphenidate, Physical Therapy, Atomoxetine
- Drug · Other
- Lead sponsor
- Hubert Fernandez
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Methamphetamine Abuse, Methamphetamine Dependence
- Interventions
- Atomoxetine, then Placebo, Placebo, then Atomoxetine
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Parkinson's Disease
- Interventions
- Atomoxetine
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Schizophrenia
- Interventions
- Diet support group, Group counseling and exercise
- Behavioral
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Catonsville, Maryland
- Conditions
- Obstructive Sleep Apnea
- Interventions
- AD036, Atomoxetine, Placebo
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Santa Ana, California • Chevy Chase, Maryland + 2 more
- Conditions
- Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Atomoxetine
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Nicotine Dependence
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- OSA
- Interventions
- AD109, Placebo
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 646 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 65
- States / cities
- Tuscaloosa, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more
- Conditions
- Attention Deficit Disorder With Hyperactivity, Substance-Related Disorders
- Interventions
- Atomoxetine hydrochloride, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 15 Years to 30 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- ATMX
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 3 Years to 5 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Post Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine 80 MG
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 34
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Colton, California + 31 more
- Conditions
- ADHD
- Interventions
- Pediasure, Nutritional counseling
- Dietary Supplement · Behavioral
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 5 Years to 9 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Alcohol Use Disorder
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 14 Years to 20 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- atomoxetine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 1,553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • El Centro, California + 67 more
- Conditions
- Alzheimer Disease
- Interventions
- atomoxetine hydrochloride, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 3
- States / cities
- Sherman Oaks, California • Rochester, New York • Wichita Falls, Texas
- Conditions
- Adverse Drug Reaction
- Interventions
- Pharmacogenetic Intervention Arm (pharmacogenetic testing)
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Parkinson's Disease, Freezing of Gait
- Interventions
- ATM FOG in PD
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine Hydrochloride, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 430,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- OSA - Obstructive Sleep Apnea
- Interventions
- AD109, AD504, Atomoxetine Hydrochloride, Placebo
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 25
- States / cities
- Los Angeles, California • San Diego, California • Santa Ana, California + 21 more
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Atomoxetine Hydrochloride, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- ADHD, Comorbid Alcohol Abuse
- Interventions
- Atomoxetine, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 14
- States / cities
- El Centro, California • Poway, California • San Diego, California + 11 more